Perfluorohexyloctane

Summary

Perfluorohexyloctane (CHEMBL5314588) is an approved small-molecule ophthalmology drug; indicated across 3 conditions including dry eye syndrome and retinal detachment.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 9
• Chemistry: 432.26 Da · C14H17F13

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5314588
Name	Perfluorohexyloctane
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	10477896
ChEBI	CHEBI:229658
Molecular formula	C14H17F13
Molecular weight	432.26
InChIKey	WRYIIOKOQSICTB-UHFFFAOYSA-N

SMILES: CCCCCCCCC(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F

IUPAC name: 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotetradecane

ChEBI definition: A fluoroalkane that is tetradecane in which all of the hydrogen atoms at positions 1, 2, 3, 4, 5, and 6 have been replaced by fluorine atoms. It is an ophthalmic solution used to treat the signs and symptoms of dry eye disease.

Pharmacological roles (ChEBI): ophthalmology drug, nonionic surfactant.

Also known as: F6H8, Miebo, NOV-03, Nov03, NOV03, Perfluorohexyloctane, Perfluorohexyloctano, PERFLUOROHEXYLOCTANE

Patent coverage: 158 distinct patent families (511 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
dry eye syndrome	4	MONDO:0006733	EFO:1000906
retinal detachment	2	MONDO:0008375	EFO:0005773

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE4	4
PHASE3	3
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06565650	PHASE4	ACTIVE_NOT_RECRUITING	A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.
NCT06176651	PHASE4	COMPLETED	Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers
NCT06309953	PHASE4	COMPLETED	A Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease
NCT06346340	PHASE4	COMPLETED	A Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry and Postoperative Refractive Accuracy
NCT04139798	PHASE3	COMPLETED	Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)
NCT04140227	PHASE3	COMPLETED	Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)
NCT04567329	PHASE3	COMPLETED	Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)
NCT07128628	PHASE2	RECRUITING	A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
NCT03333057	PHASE2	COMPLETED	Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).